Next, the 27 migration-enhancing compounds were validated at four concentrations, 1, 5, 25, and 125 μM, in four human melanoma cell lines, SK-MEL-30 and IPC-298 which harbor NRAS mutations, and SK-MEL-3 and A-375 which harbor BRAF mutations, using the IncuCyte system. The gene discussed is NRAS; the disease is melanoma.